Market Overview

From Earlier: Amgen Announces Analysis Of Rilotumumab Data Identifies A Potential Predictive Biomarker For Patients With Gastric Or Gastroesophageal Cancer

Share:

Amgen (NASDAQ: AMGN) announced yesterday results from an exploratory biomarker analysis evaluating MET expression as a predictor of clinical response to rilotumumab (AMG 102). This analysis, conducted on a previously reported Phase 2 study of rilotumumab in patients with locally advanced or metastatic gastric or gastroesophageal cancer, showed that treatment with rilotumumab in combination with chemotherapy improved median overall survival (OS) in patients whose tumors exhibited high MET protein expression.

Full results of the study will be presented in an oral presentation at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) on June 2 (Abstract 4005, 4:45 p.m. - 5:00 p.m. CDT, E Hall D1).

Posted-In: News FDA

 

Related Articles (AMGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→